NASDAQ:MRTX - Mirati Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $163.43
  • Forecasted Upside: -9.31 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$180.20
▼ -0.05 (-0.03%)
1 month | 3 months | 12 months
Get New Mirati Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$163.43
▼ -9.31% Downside Potential
This price target is based on 15 analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $163.43, with a high forecast of $222.00 and a low forecast of $85.00. The average price target represents a -9.31% upside from the last price of $180.20.
Buy
The current consensus among 15 investment analysts is to buy stock in Mirati Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/3/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
8/1/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/21/2020BMO Capital MarketsBoost Price TargetMarket Perform$101.00 ➝ $176.00High
i
10/16/2020HC WainwrightBoost Price TargetBuy$185.00 ➝ $222.00High
i
Rating by E. White at HC Wainwright
10/8/2020CSFBBoost Price TargetOutperform$140.00 ➝ $190.00Medium
i
10/8/2020Credit Suisse GroupBoost Price TargetOutperform$140.00 ➝ $190.00Medium
i
9/28/2020Bank of AmericaInitiated CoverageNeutral$172.00Low
i
9/28/2020BofA SecuritiesInitiated CoverageNeutral$172.00Low
i
9/21/2020OppenheimerBoost Price TargetOutperform$133.00 ➝ $190.00Low
i
9/21/2020Piper SandlerBoost Price TargetOverweight$145.00 ➝ $170.00Low
i
9/18/2020CitigroupDowngradeBuy ➝ Neutral$127.00 ➝ $183.00Medium
i
9/17/2020HC WainwrightBoost Price TargetBuy$163.00 ➝ $185.00High
i
Rating by E. White at HC Wainwright
8/10/2020OppenheimerBoost Price Target$105.00 ➝ $133.00Medium
i
8/10/2020HC WainwrightReiterated RatingBuy$163.00Medium
i
Rating by E. White at HC Wainwright
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$135.00 ➝ $140.00Medium
i
8/7/2020BarclaysBoost Price TargetOverweight$123.00 ➝ $143.00Medium
i
7/29/2020Credit Suisse GroupBoost Price TargetOutperform$115.00 ➝ $135.00Medium
i
5/1/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$116.00High
i
4/16/2020Goldman Sachs GroupInitiated CoverageBuy$151.00High
i
3/30/2020OppenheimerLower Price TargetOutperform$129.00 ➝ $105.00High
i
3/12/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$88.00High
i
2/28/2020HC WainwrightReiterated RatingBuy$134.00 ➝ $126.00High
i
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$101.00Low
i
1/24/2020HC WainwrightReiterated RatingBuy$117.00 ➝ $134.00Medium
i
1/7/2020CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
11/5/2019GuggenheimBoost Price TargetBuy$116.00 ➝ $128.00Low
i
Rating by Michael Schmidt at Guggenheim
10/29/2019Cantor FitzgeraldBoost Price TargetNeutral$81.00 ➝ $85.00High
i
10/18/2019CowenReiterated RatingBuyLow
i
Rating by Chris Shibutani at Cowen Inc
10/17/2019HC WainwrightReiterated RatingBuyHigh
i
10/9/2019CitigroupSet Price TargetBuy$130.00Low
i
Rating by Yigal Nochomovitz at Citigroup Inc.
9/27/2019Credit Suisse GroupSet Price TargetPositive ➝ Buy$120.00 ➝ $115.00Low
i
9/24/2019GuggenheimUpgradeNeutral ➝ Buy$116.00High
i
9/11/2019B. RileyLower Price TargetNeutral$92.00 ➝ $83.00High
i
Rating by H. Polishetty at B. Riley
9/9/2019Cantor FitzgeraldLower Price TargetNeutral$85.00 ➝ $81.00High
i
Rating by Varun Kumar at Cantor Fitzgerald
9/9/2019Jefferies Financial GroupUpgradeHold ➝ Buy$89.00 ➝ $105.00Medium
i
8/6/2019HC WainwrightReiterated RatingBuy$117.00High
i
8/6/2019CowenReiterated RatingBuyHigh
i
8/2/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$101.00 ➝ $85.00High
i
7/31/2019SVB LeerinkSet Price TargetBuy$118.00High
i
Rating by Andrew Berens at SVB Leerink LLC
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$86.00Medium
i
7/12/2019JPMorgan Chase & Co.Boost Price TargetNeutral$70.00 ➝ $101.00Low
i
6/19/2019B. RileyDowngradeBuy ➝ Neutral$60.00 ➝ $92.00Medium
i
Rating by H. Polishetty at B. Riley
6/7/2019GuggenheimDowngradeBuy ➝ Neutral$95.56Medium
i
6/5/2019HC WainwrightReiterated RatingBuy ➝ Buy$84.00 ➝ $117.00Low
i
6/5/2019BarclaysBoost Price TargetOverweight$85.00 ➝ $123.00Low
i
6/4/2019SunTrust BanksBoost Price TargetBuy$120.00Medium
i
6/4/2019Piper Jaffray CompaniesBoost Price TargetOverweight$85.00 ➝ $125.00Medium
i
6/4/2019CowenReiterated RatingBuyHigh
i
6/4/2019Cantor FitzgeraldBoost Price TargetNeutral ➝ Positive$66.00 ➝ $85.00High
i
Rating by Varun Kumar at Cantor Fitzgerald
6/4/2019CitigroupUpgradeNeutral ➝ Buy$76.00 ➝ $132.00High
i
5/16/2019Cantor FitzgeraldReiterated RatingHoldHigh
i
Rating by Varun Kumar at Cantor Fitzgerald
5/15/2019CowenReiterated RatingBuyHigh
i
5/1/2019Cantor FitzgeraldReiterated RatingHold$66.00High
i
Rating by Varun Kumar at Cantor Fitzgerald
4/17/2019JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$72.00High
i
4/2/2019Cantor FitzgeraldSet Price TargetHold$66.00Low
i
Rating by Varun Kumar at Cantor Fitzgerald
3/25/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$85.00Medium
i
3/19/2019OppenheimerReiterated RatingBuyMedium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/13/2019CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
3/7/2019OppenheimerSet Price TargetBuy$81.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/4/2019Cantor FitzgeraldInitiated CoverageNeutral$66.00Medium
i
Rating by V. Kumar at Cantor Fitzgerald
3/4/2019CitigroupBoost Price TargetBuy ➝ Neutral$64.00 ➝ $77.00Low
i
2/15/2019SVB LeerinkReiterated RatingOutperformHigh
i
Rating by A. Berens at SVB Leerink LLC
2/15/2019HC WainwrightReiterated RatingBuyMedium
i
2/15/2019Piper Jaffray CompaniesInitiated CoverageOverweight$85.00Medium
i
1/16/2019OppenheimerBoost Price TargetOutperform$57.00 ➝ $65.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
11/30/2018B. RileyInitiated CoverageBuy ➝ Buy$60.00Low
i
Rating by H. Polishetty at B. Riley
11/15/2018Jefferies Financial GroupReiterated RatingHold$37.00High
i
11/12/2018HC WainwrightReiterated RatingBuy$65.00High
i
11/11/2018OppenheimerSet Price TargetBuy$57.00Medium
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
10/30/2018OppenheimerSet Price TargetBuy$62.00Low
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
10/29/2018GuggenheimUpgradeNeutral ➝ BuyLow
i
10/22/2018CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
9/27/2018CowenReiterated RatingBuyHigh
i
Rating by Chris Shibutani at Cowen Inc
9/17/2018GuggenheimInitiated CoverageNeutralLow
i
7/20/2018HC WainwrightBoost Price TargetBuy$63.00High
i
7/9/2018OppenheimerBoost Price TargetOutperform$35.00 ➝ $62.00High
i
7/5/2018CitigroupBoost Price TargetBuy$37.00 ➝ $64.00Medium
i
6/28/2018CowenReiterated RatingBuyMedium
i
6/19/2018SunTrust BanksBoost Price TargetBuy$60.00Medium
i
3/12/2018HC WainwrightBoost Price TargetBuy$40.00High
i
Rating by E. White at HC Wainwright
3/12/2018BarclaysInitiated CoverageOverweight$44.00High
i
3/9/2018SunTrust BanksBoost Price TargetPositive ➝ Buy$40.00High
i
3/5/2018CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $37.00High
i
1/9/2018HC WainwrightBoost Price TargetBuy ➝ Buy$17.00 ➝ $21.00N/A
i
Rating by E. White at HC Wainwright
1/8/2018OppenheimerSet Price TargetBuy$18.00High
i
Rating by Leah R. Cann at Oppenheimer Holdings Inc.
12/21/2017CowenInitiated CoverageOutperformLow
i
11/22/2017OppenheimerReiterated RatingBuy$18.00N/A
i
11/14/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00 ➝ $17.00N/A
i
Rating by E. White at HC Wainwright
11/14/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$9.00N/A
i
Rating by M. Schmidt at SVB Leerink LLC
11/7/2017HC WainwrightReiterated RatingBuyN/A
i
Rating by E. White at HC Wainwright
10/12/2017SunTrust BanksReiterated RatingBuy$13.00N/A
i
10/12/2017HC WainwrightReiterated RatingBuy ➝ Buy$20.00N/A
i
Rating by E. White at HC Wainwright
10/2/2017SunTrust BanksReiterated RatingBuy$13.00High
i
9/19/2017CIBCInitiated CoverageOutperform ➝ Outperform$18.00Low
i
9/19/2017CitigroupReiterated RatingBuy$8.00 ➝ $16.00Low
i
9/18/2017OppenheimerInitiated CoverageOutperform$18.00Medium
i
9/15/2017SVB LeerinkBoost Price TargetMkt Perform ➝ Market Perform$7.00 ➝ $9.00N/A
i
8/4/2017Jefferies Financial GroupSet Price TargetHold$5.00Low
i
Rating by Maury Raycroft at Jefferies Financial Group Inc.
6/12/2017Jefferies Financial GroupReiterated RatingHold$4.50Medium
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
4/12/2017Jefferies Financial GroupReiterated RatingHold$5.50High
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
3/11/2017HC WainwrightSet Price TargetBuy$12.00 ➝ $10.00N/A
i
Rating by S. Deepak at HC Wainwright
3/11/2017Jefferies Financial GroupReiterated RatingHold$5.00 ➝ $5.50N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
1/9/2017Jefferies Financial GroupReiterated RatingHold$5.00N/A
i
11/18/2016Avondale PartnersDowngradeOutperform ➝ Market PerformN/A
i
11/17/2016HC WainwrightInitiated CoverageBuy$12.00N/A
i
Rating by S. Deepak at HC Wainwright
11/11/2016SVB LeerinkReiterated RatingHold$7.00N/A
i
11/4/2016WedbushReiterated RatingOutperform$12.00N/A
i
Rating by Heather Behanna at Wedbush
10/4/2016WedbushReiterated RatingOutperform$12.00N/A
i
Rating by Heather Behanna at Wedbush
8/19/2016Piper Jaffray CompaniesReiterated RatingNeutralN/A
i
Rating by Initiated, Yesterday Hold at Piper Jaffray Companies
8/18/2016Piper Jaffray CompaniesSet Price TargetHold$7.00N/A
i
Rating by steven breazzano at Piper Jaffray Companies
8/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$14.00 ➝ $7.00N/A
i
Rating by Initiated, Yesterday Hold at Piper Jaffray Companies
6/6/2016BarclaysLower Price TargetOverweight$41.00 ➝ $27.00N/A
i
Rating by Jonathan Eckard at Barclays PLC
6/6/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$37.00 ➝ $20.00N/A
i
Rating by M. Schmidt at SVB Leerink LLC
6/6/2016CitigroupLower Price TargetBuy$30.00 ➝ $23.00N/A
i
6/6/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$27.00 ➝ $17.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
6/6/2016WedbushLower Price TargetOutperform$29.00 ➝ $27.00N/A
i
Rating by Heather Behanna at Wedbush
5/24/2016WedbushReiterated RatingOutperform$41.00 ➝ $29.00N/A
i
5/12/2016Piper Jaffray CompaniesInitiated CoverageHold$20.00 ➝ $17.00N/A
i
5/9/2016Jefferies Financial GroupReiterated RatingBuy$29.00 ➝ $27.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
5/6/2016WedbushReiterated RatingOutperform$45.00 ➝ $41.00N/A
i
5/6/2016Avondale PartnersUpgradeMarket Perform ➝ Market Outperform$22.00 ➝ $20.00N/A
i
3/10/2016WedbushReiterated RatingOutperform$45.00N/A
i
3/10/2016SVB LeerinkLower Price TargetOutperform$50.00 ➝ $37.00N/A
i
3/10/2016Jefferies Financial GroupLower Price TargetBuy$33.00 ➝ $29.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
3/1/2016SunTrust BanksInitiated CoverageBuy$32.00N/A
i
2/24/2016BarclaysLower Price TargetBuy$50.00 ➝ $41.00N/A
i
Rating by Jonathan Eckard at Barclays PLC
2/19/2016CitigroupLower Price Target$48.00 ➝ $34.00N/A
i
2/17/2016Jefferies Financial GroupReiterated RatingBuy$43.00 ➝ $33.00N/A
i
2/17/2016Jefferies Financial GroupInitiated CoverageBuyN/A
i
1/13/2016CitigroupUpgradeNeutral ➝ Buy$48.00N/A
i
11/23/2015CitigroupInitiated CoverageNeutralN/A
i
(Data available from 10/24/2015 forward)
Mirati Therapeutics logo
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $180.20
$177.80
$184.05

50 Day Range

MA: $165.55
$132.11
$198.62

52 Week Range

Now: $180.20
$66.01
$203.77

Volume

456,291 shs

Average Volume

500,948 shs

Market Capitalization

$8.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85